Spero Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se espera que el BPA de Spero Therapeuticscrezca en un 47.6% al año.
Información clave
n/a
Tasa de crecimiento de los beneficios
47.61%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 25.2% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy
Summary Spero Therapeutics' lead asset is an oral carbapenem tebipenem for cUTI. This asset achieved Phase 3 noninferiority. In fact, this data supports GSK’s NDA resubmission strategy. The prior FDA setback from ADAPT-PO was addressed through PIVOT-PO. The new PIVOT-PO trial was actually stopped early after strong interim efficacy results. So, I believe their data is quite favorable this time. Also, SPRO’s partnership economics are meaningful. They can soon receive sizable resubmission milestone payments and royalties tied to commercialization. In my view, SPRO’s current valuation seems too low relative to the TAM they can unlock with tebipenem. So, I rate them a speculative 'Buy' at these levels. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 26%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders would be excited to see that the share price has had a great...
Positive Phase III Efficacy Will Unlock Expanded Antibiotic Markets
The downward revision in Spero Therapeutics’ consensus price target largely reflects declines in its future P/E multiple and net profit margin, resulting in a lower fair value estimate of $4.00. What's in the News The phase III PIVOT-PO trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), was stopped early due to efficacy, following an Independent Data Monitoring Committee recommendation.Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?
NasdaqGS:SPRO 1 Year Share Price vs Fair Value Explore Spero Therapeutics's Fair Values from the Community and select...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
With a price-to-sales (or "P/S") ratio of 3.1x Spero Therapeutics, Inc. ( NASDAQ:SPRO ) may be sending very bullish...
Successful Phase III Trial Will Redefine Treatment For Complicated UTIs
Successful PIVOT-PO trial and regulatory approval could propel revenue growth, leveraging a strategic partnership with GSK for commercialization.Spero Therapeutics, Inc. (NASDAQ:SPRO) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares are down a considerable 27% in...Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Summary Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM. Despite risks, SPRO's valuation is attractive, with significant upside potential from tebipenem milestones and possible pipeline progress. Read the full article on Seeking AlphaThere Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.5x might make it look like a strong buy...Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price
Spero Therapeutics, Inc.'s ( NASDAQ:SPRO ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Spero Therapeutics Delivers On Game Plan To Create Shareholder Value
Summary Spero Therapeutics, Inc. has continued to build and advance its pipeline over the past several months and is now on the verge of generating landmark data with multi-bagger potential. Spero has excellent downside protection and additional upside from the payments from the Tebipenem HBr deal with GSK. Spero's significant undervaluation and potential path forward are highlighted in the peer comparison. Read the full article on Seeking AlphaSpero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares have continued their recent momentum with a 27% gain in the last month...Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
The Spero Therapeutics, Inc. ( NASDAQ:SPRO ) share price has done very well over the last month, posting an excellent...Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates
Today is shaping up negative for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, with the analysts delivering a...Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth
Those holding Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shares would be relieved that the share price has rebounded 26...Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%
Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders will have a reason to smile today, with the analysts making...We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2026 | 61 | 15 | 7 | 7 | N/A |
| 12/31/2025 | 67 | 9 | -13 | -13 | N/A |
| 9/30/2025 | 41 | -44 | -28 | -28 | N/A |
| 6/30/2025 | 49 | -54 | -32 | -32 | N/A |
| 3/31/2025 | 45 | -70 | -33 | -33 | N/A |
| 12/31/2024 | 48 | -69 | -23 | -23 | N/A |
| 9/30/2024 | 106 | 4 | -18 | -18 | N/A |
| 6/30/2024 | 118 | 17 | -14 | -14 | N/A |
| 3/31/2024 | 111 | 23 | -14 | -14 | N/A |
| 12/31/2023 | 104 | 23 | -33 | -33 | N/A |
| 9/30/2023 | 78 | -2 | 29 | 29 | N/A |
| 6/30/2023 | 54 | -10 | 12 | 12 | N/A |
| 3/31/2023 | 54 | -27 | 8 | 8 | N/A |
| 12/31/2022 | 54 | -46 | -8 | -8 | N/A |
| 9/30/2022 | 9 | -102 | -80 | -80 | N/A |
| 6/30/2022 | 10 | -113 | -84 | -84 | N/A |
| 3/31/2022 | 13 | -103 | -77 | -77 | N/A |
| 12/31/2021 | 18 | -90 | -64 | -64 | N/A |
| 9/30/2021 | 17 | -79 | -53 | -53 | N/A |
| 6/30/2021 | 18 | -76 | -70 | -70 | N/A |
| 3/31/2021 | 15 | -74 | -78 | -78 | N/A |
| 12/31/2020 | 9 | -79 | -86 | -86 | N/A |
| 9/30/2020 | 11 | -85 | -87 | -87 | N/A |
| 6/30/2020 | 12 | -84 | -75 | -75 | N/A |
| 3/31/2020 | 12 | -80 | -63 | -62 | N/A |
| 12/31/2019 | 18 | -61 | N/A | -50 | N/A |
| 9/30/2019 | 16 | -47 | N/A | -46 | N/A |
| 6/30/2019 | 12 | -39 | N/A | -42 | N/A |
| 3/31/2019 | 11 | -36 | N/A | -39 | N/A |
| 12/31/2018 | 4 | -42 | N/A | -40 | N/A |
| 9/30/2018 | 3 | -46 | N/A | -39 | N/A |
| 6/30/2018 | 3 | -47 | N/A | -44 | N/A |
| 3/31/2018 | 3 | -50 | N/A | -44 | N/A |
| 12/31/2017 | 2 | -46 | N/A | -39 | N/A |
| 9/30/2017 | 1 | -40 | N/A | -36 | N/A |
| 6/30/2017 | 1 | -35 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -30 | N/A | -29 | N/A |
| 12/31/2016 | 0 | -30 | N/A | -29 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de SPRO es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de SPRO crezcan más rápidamente que el mercado US
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de SPRO crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de SPRO crezcan más rápidamente que el mercado de US.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de SPRO crezcan a un ritmo superior a 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SPRO se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/26 11:27 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Spero Therapeutics, Inc. está cubierta por 6 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Esther Lannie Hong | Berenberg |
| Jason Matthew Gerberry | BofA Global Research |
| Esther Lannie Hong | Brean Capital Historical (Janney Montgomery) |